УДК – 599+599.9 БИОЛОГИЧЕСКИЕ ЭФФЕКТЫ УРОТЕНЗИНА 2

– 599+599.9
2–
(
)
.
2 -
(
.
:
,
,
:
2,
,
,
)
,
,
,
.
,
,
,
,
.
2
.
2
,
,
[5, 19, 21, 23],
,
,
,
.
2
.
,
2
,
,
2
,
[1,4,5,8, 11, 13, 14, 17].
2
,
,
,
,
,
2,
[18, 19, 20,
22].
,
,
-
2
.
,
.
[11].
,
,
,
,
,
,
.
;
;
;
;
;
.
;
;
,
;
-
.
;
;
,
.
1.
2
2
. B.C.
-
[5]
2
.
(
.
0,5; 1,0; 2,0 4,0
)
- 0,9 %"
2
"
.
,
2
.
,
.
2
0,001
,
.
2
.
,
,
,
.
2
30
-
.
,
1
.
,
(0,9 %20 ± 2,5
45 - 50
2
)
1
,
2-3
.
,
10-
,
1
,
60 ± 1,5
.
.
2
4
0,5
,
0,5
.
1
,
,
,
-
,
,
,
,
.
2
,
.
,
-
.
6
.
(
= 7,0)
6·10-6
.
37°
-327
0,2
1·10-6
.
10.
60
,
-
.
.
2
,
,
.
2,1 ± 0,03
.
1·10-6
,
.
-
,
.
60
.
1016
2
.
,
2
.
-
,
,
.
,
,
,
[4, 5].
2.
2
25
14
25
(6
.
8
)
-3
(1
= 10
. [12].
.
),
1, 2
100
3
QRS
% ( < 0,05)
15,8 % ( < 0,05)
11,1
15-
,
36 % ( < 0,05)
.
.
,
QRS
29,8 % ( < 0,05),
( <
30-
0,05).
R
.
10.
32,2
R,
52,0 %
,
.
R
,
-
,
10-
R
11,1 %,
2-
,
17,1 %
( < 0,05).
-
,
.
I
,
[7].
,
,
-
3.
2
,
25
,
,
.
,
200 ± 20
25
12
.
5 %-
2
0,09 %-
.
,
,
,
II
5, 10, 15, 30, 45
60
.
.
-116
068.
,
( ./
),
,
,
,
,
[5].
,
2
25
.
10-
20,2 %,
< 0,05),
- 5-
(
27,2 %,
< 0,05).
,
3030(
.
.
)
,
60-
.
2
:
,
.
-
,
.
,
,
26,4 %
5-
,
45,4 % ( < 0,02).
.
30-
,
60.
,
,
,
,
2.
30-
2
,
,
2.
.
5-
11,1 %.
30-41
,
.
,
,
,
.
.
,
,
-
2.
-
,
,
.
,
.
2
-
,
,
,
,
.
,
2
,
,
.
,
(
),
,
,
(
(
).
25
.
)
5,
30-
60-
.
(
)
,
60-
15-
,
,
[5].
,
,
25
,
,
.
,
.
2,
NaCl
25
0,9 %-
,
[11].
4.
2
,
2
.
.
42
2
.
,
.
.
,
.
,
,
,
.
-
,
-
.
,
.
,
,
2
,
,
,
,
(
(
,
),
,
),
:
,
.
,
),
-
.
,
(
,
,
,
,
.
,
2.
,
,
,
,
,
.
,
,
.
2
.
,
.
,
4,5
,
,
.
,
,
[5].
3
,
2
.
.
30 %
,
,
,
,
,
.
,
,
,
,
.
2,
.
2
,
,
.
"
,
,
,
",
.
,
,
5.
2
2
,
.
[3].
.
2,
[11].
,
1 : 84 ± 7,76,
.
,
1 : 256 = 12,66.
.
1 : 32
-
,
,
,
1 : 512,
,
-
1:4
1:32.
-
15 %
( > 0,001).
85 %
,
-
1:16 ± 3,4,
,
,
55 %
45 % 1:15,9 ± 2,78.
1:15 ± 4,65,
-
1:16
± 2,82 ( > 0,05).
.
,
2
.
,
,
2
,
.
(
,
1:14 ± 8,62,
,
)
,
,
1:6 ± 3,
2,33
,
.
,
-
,
,
,
1:7,25 ± 2,727,
,
±
1:48
36,16.
1:4
1:512
.
2
.
- 70-
-
35
.
,
2
(
1:8
)
.
"
)
(
1:16.
"',
.
2
1:32
70-
1:124.
1:2 - 1:4,
,
.
.
90 - 96
85 - 90
.
.,
.
63 - 65
,
5
25 %-
.
351:16-1:32.
1:32
1:64,
135/90
.,
95
75 - 85
130/90
./
.
.
.
.,
90 -
.
1:64.
:
110-115/65-70
. .,
1:16–1:8.
2
- 95 - 100
./
.,
,
,
.
-
.
1.
2.
,
.
-
,
,
,
,
.
3.
2
,
,
1:128
.
4.
-
(
)
,
,
1:8
1:4.
,
,
,
2
[11].
,
,
,
.
-
,
,
.
,
,
25
45
70-
.
,
,
,
,
,
,
.
,
.
"
,
.
,
,
,
,
:
,
,
,
,
22
;
2
,
,
2
[15];
[2, 9];
[11, 16];
[6];
2
2 [10];
[11];
[11];
[11];
2 [11];
,
30 %
2 [11];
,
2;
2
,
[13]
[14].
On the basis of his own research and findings provided in the special literature the author puts to the critical analysis
the present day concepts of the biological role of urotensin II, the caudal neurosecretory system hormone in animals
and human organisms. The article shows the regulatory function of this hormone in animals and human organisms
and its participation in psychosomatic and psychoendocrine disease pathogenesis, such as cardiovascular, sexual and
reproductive systems, menstrual periods, adaptation and behavior.
The key words:Urotensin II, physiological effects, cardiovascular, sexual and reproductive system diseases, stress,
adaptation, ethology.
1.
,
.
[
,
2.
,
.
8.
]/
.
,
.
, B.C.
,
.
.-
,
. B.C.
,
V-H
XIV
.
:
.
2163812. [
.
[
]/
.
,
//
.
]/
.
. ...
.
.
.
.
, 1996. -
17.06.1997.
.
.
,
[
]/
.
, 1983. - .2. - .
.
.
,
:
//
. 1997.
]/
.
22. .7.
,
.
,
//
, 2000. . 14-17.
:
,
3
.
, B.C.
.) [
] /B.C.
,
.
,
.
//
,
).
9.
.
.
]/
,
.
//
1979 .,
[
.
.
//
. ., 1972. - . 170 -171.
,
[
669015,
09.03.1978.
3.
[
.
1980.
.(
).
4.
, B.C.
149.
5.
.
23 .
6.
.
7.
]/
. 50-
(
.
(
)
2224528,
[
] /
.
.
.
,
(
.
.
//
) 27.02.2004 .,
24.07.2001 .
,
.
10.
(
2272650,
24.10.2003 .
11.
,
)
[
.
.
]/
.
.
.
. . .
//
) 27.03.2006.
(
.
-
[
]/
.
II -
.-
:
]/
.
. 1973.
, 2009. 110
.
12.
,
.
.
[
//
13.
,
] /
:
,
16.
,
.
1-
]/
.
.
, B.C.
,
,
.
,
//
.
.-
,
.
, 2002.
.
[
15.
,
.
[
.21-23.
14.
,
.
4. .83-85.
.
(
:
.
.
.
.
.
.
, 2004.
[
] /
//
.
,
. ...
).
, 1977. .33-34 (
:
).
.
469805 [
]/
.
,
.
, B.C.
. ., 1984.
25.06.1979.
17.
, .A. Das intraspinale Organ des Menschen [
] /
.
,
.
// Medizin in Fernen Osten der UdSSR. 49 Abbildungen. Hyppokrates verlag. Stuttgart, 1975.
C.51-59.
18. AshtonN. Kidney Int. Aug.: 70(4):624-9.
19. Brkovic A., Hattenberger A., Kostenis E., Klabunde T. Flohr S., Kurz M., Bourgault S.,
Founier A. Functional and binding characterizations of urotenzin -related peptides in human and rat
urotenzin II-receptor assay. 2003 Sep; 306(3): 1200-9. Epub 2003 Jun 13.
20. Carotenuto A., Grieco P., Rovero P., Novelino E. Urotensin II receptor agonist // J. Curr Med
Chem. 2006: 13(3):267-75.
21. Ovcharenko E., Abassi Z., Rubinstein E. Kaballa A., Hoffman A., Winaver J. Renal effects of
human urotensin II in rats with exsperimental congestive heart failure // Nephrol Dial Transplant. 2006
May:21(5):1205-ll.
22. Platzack ., Schaffert C, Hazon N., Conlon J.M. Cardiovascular actions of dogfish urotensin I
in the dogfish, Scyliorhinus canicula // Gen Comp Endocrinol. 1998 Feb: 109(2):269-75.
23. Zeng Z.P., Liu G.Q., Li H.Z., Fan X.R., Liu D.M., Tong A.L., Zheng X., Liu The effects of
urotensin II on proliferation of pheochromocytoma cells and mRNAezpression of urotensin II and receptor in pheochromocytoma tissues // Ann N Y Acad Sci. 2006 Aug; 1073:284-9.
. –
,
.